Eric J. Ende is Director at AVADEL PHARMACEUTICALS PLC (AVDL). They have made 12 open-market trades across 2 companies since 2018, most recently 2026-02-12.
CIK 0001494386
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
12 open-market purchases totalling $1.1M since 2018, never a sale. Across 12 scored buys the stock is up 50.1% at ninety days, and 47.0 points ahead of the S&P over the same stretch.
12 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 42% | 42% | 58% |
| Avg Move | -2.6% | -4.8% | +50.1% |
| Alpha | -2.2% | -5.1% | +47.0% |
| Scored | 12 | 12 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AVDL | BUY | 2025-01-13 | 2025-01-14 | $7.84 | $235K | -13.3% | +4.1% | -10.5% |
| AVDL | BUY | 2023-05-18 | 2023-05-19 | $13.93 | $181K | -4.2% | -0.9% | -11.6% |
| AVDL | BUY | 2022-11-22 | 2022-11-23 | $7.80 | $156K | +2.8% | -14.0% | -0.5% |
| AVDL | BUY | 2022-05-31 | 2022-06-01 | $2.22 | $78K | -3.8% | +9.8% | +181.6% |
| AVDL | BUY | 2022-05-27 | 2022-05-31 | $2.45 | $37K | +8.0% | +8.4% | +200.9% |
| AVDL | BUY | 2020-09-17 | 2020-09-18 | $5.79 | $98K | -22.1% | -17.2% | +18.5% |
| AVDL | BUY | 2020-08-13 | 2020-08-17 | $7.79 | $39K | -28.5% | -34.1% | -18.8% |
| AVDL | BUY | 2020-08-12 | 2020-08-13 | $7.76 | $116K | -1.1% | -31.6% | -27.8% |
| AVDL | BUY | 2019-12-04 | 2019-12-05 | $5.97 | $60K | +11.0% | +15.6% | +69.9% |
| AVDL | BUY | 2019-11-15 | 2019-11-19 | $4.98 | $50K | +20.2% | +23.1% | +36.0% |
| MTNB | BUY | 2019-08-20 | 2019-08-22 | $0.66 | $13K | +0.7% | -13.2% | +78.3% |
| MTNB | BUY | 2019-08-19 | 2019-08-21 | $0.68 | $14K | -0.5% | -7.9% | +85.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.